Impact of the dosing of basic drugs on the risk of rehospitalization in patients with chronic heart failure


Cite item

Full Text

Abstract

Aim. To investigate the impact of doses of the drugs, which have been achieved during adjustment and account for less or more than 50% of the maximal therapeutic ones on the risk of rehospitalization. Subjects and methods. The data of the Pavlov Register were used to assess the treatment of patients with chronic heart failure. To assess the risk of rehospitalization in relation of the dose of a drug, all the doses were represented in percentage terms depending on the maximum therapeutic one. Results. The risk of hospitalization during 6 months in the patients receiving angiotensin-converting enzyme inhibitors at a dose of 25% or less of the therapeutic one was 21.18% (odds ratio (OR), 1.41; 95% confidence interval (CI), 1.13—1.76), that at doses of 50 and 100% of the therapeutic one was 16% (OR, 0.71; 95% CI, 0.56—0.88) and 34% (OR, 0.51; 95% CI, 0.43—0.60), respectively. The risk of rehospitalization in the patients taking β-blockers at doses of 25, 50, and 100% of the therapeutic one was 26% (OR, 1.05; 95% CI, 0.94—1.17), 23% (OR, 0.902; 95% CI, 0.75—1.07), and 6.25% (OR, 0.19; 95% CI, 0.07—0.56), respectively. The combined analysis of the dose and use frequency of diuretics showed that the highest risk of rehospitalization turned was noted in the patients using a single dose of 100 mg of furosemide (4.2% of cases) once weekly and was as high as 39% (OR, 0.45; 95% CI, 1.04—1.98). Conclusion. The risk of rehospitalization is largely determined by the dosing factor in outpatient settings. Increasing the doses during adjustment reduces the risk of rehospitalization.

References

  1. O’Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023.
  2. Rudiger A, Harjola V-P, Müller A, Mattila E, Säila P, Nieminen M, Follath F. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail. 2005;7(4): 662-670. doi: 10.1016/j.ejheart.2005.01.014.
  3. Gheorghiade M, Vaduganathan M, Fonarow G, Bonow RO. Rehospitalization for Heart Failure Problems and Perspectives. J Am Coll Cardiol. 201329;61(4):391-403. doi: 10.1016/j.jacc.2012.09.038.
  4. Арутюнов А.Г. Возможны ли новые подходы к неотложной терапии декомпенсации ХСН? Сложность оценки конечных точек. Сердечная недостаточность. 2009;10(5):254-258.
  5. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013;14(7):379-472.
  6. Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Сердечная недостаточность. 2014;4(1):135-141.
  7. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart FailureA Report From the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-777. doi: 10.1016/j.jacc.2007.04.064.
  8. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC; ADHERE Scientific Advisory Committee and Investigators. Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function. J Am Coll Cardiol. 2006;47(1):7 6-84.
  9. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312-2318. doi: 10.1161/01.cir.100.23.2312.
  10. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Frøland SS, Fowler M. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34(7):2061-2067. doi: 10.1016/s0735-1097(99)00495-7.
  11. Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (павловский регистр). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, определяемых при физикальном и инструментальном обследовании пациентом с декомпенсацией кровообращения. Сердечная недостаточность. 2014;15(2):67-75.
  12. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med. 2001;344(22):1651-1658.
  13. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sørensen R, Folke F, Gadsbøll N, Rasmussen S, Køber L, Madsen M, Torp-Pedersen C. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation. 2007;116(7):737-744. doi: 10.1161/circulationaha.106.669101.
  14. Ерофеева С.Б. Фармакоэпидемиологическое исследование : как сегодня лечат пациентов с хронической сердечной недостаточностью в поликлиниках г. Москвы. Лечебное дело. 2006;2.
  15. Арутюнов Г.П., Драгунов Д.О., Соколова А.В. Влияние петлевых диуретиков с различным периодом полувыведения на динамику натрийуреза и показатели, характеризующие состояние тубулоинтерстициальной ткани почек. Терапевтический архив. 2014;86(6):38-44.
  16. Arutynov GP. Diuretic administration in fluid retention syndrome. EJIM. 2014;01(01):62-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies